The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
Open Access
- 1 May 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (Supplement) , S202-S209
Abstract
Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in development for the treatment of infections caused by Acinetobacter, including multidrug-resistant (MDR) isolates. Although sulbactam is a β-lactamase inhibitor of a subset of Ambler class A enzymes, it also demonstrates intrinsic antibacterial activity against a limited number of bacterial species, including Acinetobacter, and has been used effectively in the treatment of susceptible Acinetobacter-associated infections. Increasing prevalence of β-lactamase–mediated resistance, however, has eroded the effectiveness of sulbactam in the treatment of this pathogen. Durlobactam is a rationally designed β-lactamase inhibitor within the diazabicyclooctane (DBO) class. The compound demonstrates a broad spectrum of inhibition of serine β-lactamase activity with particularly potent activity against class D enzymes, an attribute which differentiates it from other DBO inhibitors. When combined with sulbactam, durlobactam effectively restores the susceptibility of resistant isolates through β-lactamase inhibition. The present review describes the pharmacokinetic/pharmacodynamic (PK/PD) relationship associated with the activity of sulbactam and durlobactam established in nonclinical infection models with MDR Acinetobacter baumannii isolates. This information aids in the determination of PK/PD targets for efficacy, which can be used to forecast efficacious dose regimens of the combination in humans.Keywords
Funding Information
- Entasis Therapeutics
This publication has 34 references indexed in Scilit:
- Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysisClinical Microbiology and Infection, 2014
- Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with CeftolozaneAntimicrobial Agents and Chemotherapy, 2013
- Kinetics of Avibactam Inhibition against Class A, C, and D β-LactamasesJournal of Biological Chemistry, 2013
- In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumanniiJournal of Antimicrobial Chemotherapy, 2013
- Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2012
- High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumanniiScandinavian Journal of Infectious Diseases, 2007
- Bacteremia Due to Acinetobacter baumannii: Epidemiology, Clinical Findings, and Prognostic FeaturesClinical Infectious Diseases, 1996
- Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteersAntimicrobial Agents and Chemotherapy, 1991
- In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticusJournal of Antimicrobial Chemotherapy, 1990
- Sulbactam: Biochemical Factors Involved in Its Synergy with AmpicillinClinical Infectious Diseases, 1986